Shyam Ramachandran, Ph.D., is an Executive Director in Genomic Medicine for Neurological and Immunological Diseases at Sanofi. He leads platform and portfolio strategy across genomic medicine modalities, including AAV gene therapy, RNA-based therapeutics, and vectorized biologics, with a focus on enabling cross-therapeutic area innovation in neuroscience and immunology.

Dr. Ramachandran has a strong track record of advancing complex therapeutic programs from early discovery through development candidate nomination, contributing to multiple candidates across neurodegeneration, lysosomal storage disorders, and peripheral neuropathies. His work integrates translational biology, in vivo pharmacology, and biomarker strategy to drive clinically actionable insights.